Simon will take over from current ABPI President, Chris Brinsmead of AstraZeneca (UK), on 28 April this year. He will serve for a one-year term, with the option for re-election for a further 12 months.
“I am pleased to have the opportunity to represent our industry in the UK at such an important time for the pharmaceutical sector. The UK Government has recognised the importance of the life science industry. It is both an engine of growth to support economic recovery and a continuing source of new medicines and vaccines to help the NHS deliver improved health during a time of limited resources. Against this backdrop, the industry itself is going through a period of considerable and rapid change,” said Simon.
“Patients, the NHS and society at large need access to high quality care. Innovative new medicines and vaccines form an important part of this. We should work together to develop health policies that encourage innovation, deliver value to patients and society, and help the NHS to be efficient and sustainable.
“Over the last couple of years, we have worked closely and constructively with the UK Government to identify effective solutions to these challenges. The ABPI looks forward to continued cooperation with the Government, life science sector colleagues, the NHS, patient groups and other important stakeholders. In taking over as President from Chris Brinsmead, I look forward to extending the progress that has been made under his leadership.”
Simon Jose leads the UK Pharmaceuticals business of GSK, a leading supplier of medicines and vaccines to the NHS, providing treatments for conditions such as asthma, COPD, depression, diabetes, epilepsy, HIV/AIDS, and infections (antibiotics), as well as a wide range of vaccines to prevent childhood illnesses. Simon began his career with GSK in 1986 and since then has held various sales and marketing roles of increasing seniority, both in Europe and North America, before assuming his current role in February 2008. He has a BSc in Medical Biochemistry with Honours in Physiology. Simon has been a member of the ABPI Board of Management since May 2008. He is married with three children.
Commenting on Simon’s appointment, Richard Barker, Director General, ABPI, said, “This is a crucial year in our relationship with the Government, especially as this is a general election year. As we have seen with the recent publication of the Office for Life Sciences 2010 report, there is significant benefit to be had from collaboration between government, the NHS, academia and the industry to deliver truly tangible results. Continued commitment to this strategy is crucial to the further positive development of the life sciences sector. I very much look forward to working with Simon to continue the positive progress being made.”
The ABPI is the globally respected voice of the innovative pharmaceutical industry, whose world class experts work with Government, regulators and other stakeholders to promote a receptive environment for a strong and progressive industry in the UK, capable of providing the best medicines to patients.
The ABPI is a powerful and respected force for positive change – within the world of biomedical research and within the health service that depends on its products. As the industry’s chosen mechanism to engage with its stakeholders, it ensures that the UK remains a world leader in creating, valuing and accessing innovation. It does so by combining the talents of researchers, companies, patients, professionals and external experts to creatively tackle the barriers to innovation wherever they may be found.
For further information, please visit www.abpi.org.uk
Notes to Editors:
An electronic photograph of Simon Jose is available on request